neobookRx
DrugsLevel 4 LocalisationS5CAPEML

Cyclobenzaprine Hydrochloride

AnticholinergicCentrally-acting muscle relaxant

Indications

Registered South African indications:

  • Muscle spasm

Cautions

Contraindications

  • Hypersensitivity to the active ingredient or any of its excipients
  • Dysrhythmias
  • Conduction disturbances
  • Congestive heart failure
  • Recent myocardial infarction
  • Hyperthyroidism
  • Coadministration with monoamine oxidase inhibitors or use within 14 days of their use

Cautions

  • Pregnancy
  • Breastfeeding
  • Hepatic impairment
  • Elderly
  • Urinary retention
  • Angle-closure glaucoma
  • Increased intraocular pressure
  • History of epilepsy
  • May impair the ability to drive and operate machinery

Adult dosage

Forms avail. in SA and covered in this monograph: cap

Muscle spasm associated with acute musculoskeletal conditions

  • Oral (cap): 15mg; dly; Max: 30mg/24hrs


Do not use longer than 2-3 weeks 

Paediatric dosage

Not established for use in children

Special populations

Pregnancy

  • Caution; no evidence of risk in studies
  • The safe use of cyclobenzaprine hydrochloride has not been established in pregnancy.  Animal studies have not demonstrated a foetal risk 

Breastfeeding

  • Caution; not recommended
  • Excretion of cyclobenzaprine in breast milk is unknown. The potential risk of adverse effects to breastfeeding infants cannot be excluded, therefore,  caution is recommended when administering to breastfeeding mothers

Renal Impairment 

Hepatic Impairment 

Elderly 

Porphyria Information

Drugs in Sport

  • Permitted - No warnings

Adverse reactions

Central Nervous System Disorders 

  • Seizures 
  • Ataxia
  • Vertigo 
  • Dysarthria 
  • Tremors 
  • Hypertonia 
  • Muscle twitching 
  • Disorientation 
  • Insomnia
  • Depressed mood 
  • Abnormal sensations 
  • Anxiety 
  • Agitation 
  • Psychosis
  • Abnormal thinking and dreaming 
  • Hallucinations
  • Excitement 
  • Paresthesia 
  • Diplopia 
  • Tinnitus 
  • Decreased or increased libido 
  • Abnormal gait 
  • Delusions
  • Aggressive behaviour 
  • Paranoia 
  • Peripheral neuropathy 
  • Bell’s palsy
  • Alteration in EEG patterns 
  • Extrapyramidal symptoms

Cardiovascular Disorders

  • Tachycardia 
  • Dysrhythmia 
  • Vasodilatation 
  • Palpitation 
  • Hypotension 
  • Syncope 
  • Chest pain 
  • Myocardial infarction 
  • Heart block 
  • Stroke 
  • Hypertension 
  • Oedema

Respiratory Disorders 

  • Dyspnoea

Gastrointestinal Disorders 

  • Vomiting 
  • Anorexia 
  • Diarrhoea 
  • Gastrointestinal pain 
  • Gastritis 
  • Thirst 
  • Flatulence 
  • Ageusia 
  • Paralytic ileus 
  • Tongue discolouration
  • Stomatitis 
  • Parotid swelling

Hepatobiliary Disorders 

  • Abnormal hepatic function tests
  • Hepatitis 
  • Jaundice 
  • Cholestasis

Genitourinary Disorders  

  • Urinary frequency
  • Urinary retention 
  • Impaired urination
  • Dilatation of urinary tract 
  • Impotence 
  • Testicular swelling 
  • Gynaecomastia 
  • Breast enlargement 
  • Galactorrhea

Endocrine & Metabolic Disorders 

  • Disturbances of blood glucose levels 
  • Weight gain or loss 
  • Syndrome of inappropriate antidiuretic hormone  secretion

Musculoskeletal Disorders 

  • Local weakness 
  • Myalgia

Skin and Subcutaneous Tissue Disorders 

  • Photosensitisation
  • Alopecia
  • Pruritus 
  • Facial oedema
  • Urticarial 
  • Rash

Immune, Blood and Lymphatic System Disorders 

  • Purpura 
  • Bone marrow depression 
  • Leucopenia 
  • Eosinophilia 
  • Thrombocytopenia 
  • Anaphylaxis 
  • Angioedema

Interactions

  • Monoamine oxidase inhibitors
  • Central nervous system depressants
  • Guanethidine
  • Tramadol
  • Anticholinergic medication

Monitoring

None routine

Mechanism of action

Cyclobenzaprine acts primarily within the central nervous system at the level of the brain stem. However, it does seem to act to some degree at the level of the spinal cord, which may contribute to its overall skeletal muscle relaxant activity. The net effect of cyclobenzaprine is a reduction of tonic somatic motor activity

Dosage forms

  • Capsule

Formulation

Capsule 15mg

  • Myprocam (Adcock) originator

Capsule 30mg

  • Myprocam (Adcock) originator

References

1. Myprocam 15mg, 30mg extended release capsule, Adcock Ingram Ltd:Date of registration: 6 Mar 2014 [https://drive.google.com/drive/u/0/folders/1TO3Wm7Nu5Rrt9F42qJRf5TWq7rrhw5to] 2. Drugs.com: Cyclobenzaprine; Downloaded online 28 Nov 2018 [https://drive.google.com/drive/u/0/folders/1TO3Wm7Nu5Rrt9F42qJRf5TWq7rrhw5to] 3. S Afr Pharm J 2015 Vol 82 No 5 - Myprocam - Drug Info new product focus 4. EMG-Clinical Pharmacologist - Literature Review. 5. Amrix (cyclobenzaprine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals, Inc; May 2016. 6. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002;16(1):64-70.. 7. UpToDate; Cyclobenzaprine; Accessed online 11 Dec 2018 [https://www.uptodate.com/contents/cyclobenzaprine-drug-information?search=cyclobenzaprine&source=panel_search_result&selectedTitle=1~36&usage_type=panel&kp_tab=drug_general&display_rank=1] 8. NAPOS The Drug Database for Acute Porphyria: M03BX08 Cyclobenzaprine; Accessed online 11 Dec 2018 [http://www.drugs-porphyria.org/languages/UnitedKingdom/s3.php?l=gbr&atc_code=M03BX08] 9. South African Institute for Drug-Free Sport; Myprocam; Accessed online 11 Dec 2018 [http://www.drugfreesport.org.za/online-medication-check/] 10. Afritox; Cyclobenzaprine hydrochloride; Accessed online: 30 June 2020 [http://www.afritox.co.za/hp/SingleToxin/SingleToxin.aspx?SingleToxinID=20269] ****There is no SPC avail for this product *****recently launched in SA (2014 / 2015)

Brands & products

4 products · stale NAPPI snapshot · refreshed 5/28/2026 · 159 days old

CapsulesGeneric· 2 products

from R23.57/unit
ProductStrengthPackSchedSEPUnitDisp feeNAPPI
Pribemak 1515 mg30S5R707.20R23.57R188.503010186001
Pribemak 3030 mg30S5R1072.15R35.74R242.193010187001

SrcGeneric· 2 products

from R24.33/unit
ProductStrengthPackSchedSEPUnitDisp feeNAPPI
Myprocam15 mg30S5R729.93R24.33R191.85720360001
Myprocam30 mg30S5R1108.54R36.95R247.55720361001
Trade names (1)
  • Myprocam

Medical aid coverage

data not yet integrated
Discovery Health
not yet integrated
  • Comprehensive Series—
  • Executive Plan—
  • KeyCare Series—
  • Priority Series—
  • Saver Series—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

Bonitas Medical Fund
not yet integrated
  • BonClassic—
  • BonComprehensive—
  • BonEssential—
  • BonFit Select—
  • BonSave—
  • BonStart—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

GEMS — Government Employees Medical Scheme
not yet integrated
  • Beryl—
  • Emerald—
  • Onyx—
  • Ruby—
  • Sapphire—
  • Tanzanite One—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

POLMED — Police Medical Aid Scheme
not yet integrated
  • Aquarium Option—
  • Efficiency Option—
  • Marine Option—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

NeoHealth® ID 14963 · updated 5/28/2024